Literature DB >> 14645918

Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques.

Yujuan Yue1, Shan Shan Zhou1, Peter A Barry1.   

Abstract

Rhesus cytomegalovirus (RhCMV) exhibits strong parallels with human CMV (HCMV) in terms of nucleic and amino acid identities, natural history, and mechanisms of persistence and pathogenesis in its natural host, rhesus macaques (Macaca mulatta). To determine whether this non-human primate model would be useful to assess vaccine strategies for HCMV, host immune responses to RhCMV glycoprotein B (gB) were evaluated in RhCMV-infected monkeys. Total protein extracts were prepared from cells transiently transfected with an expression plasmid for either the full-length gB or a derivative (gBDelta, 1-680 aa) lacking both the transmembrane domain and cytoplasmic tail. Western blot analysis showed identical reactivity of macaque sera with full-length gB and its derivative gBDelta, indicating that the immunodominant epitopes of gB are contained in the extracellular portion of the protein. Using gBDelta extract as a solid phase, a sensitive and specific ELISA was established to characterize gB antibody responses in monkeys acutely and chronically infected with RhCMV. During primary infection (seroconversion), gB-specific antibodies developed concurrently and in parallel with total RhCMV-specific antibodies. However, during chronic infection gB-specific antibody responses were variable. A strong correlation was observed between neutralizing and gB-specific antibody levels in RhCMV-seropositive monkeys. Taken together, the results of this study indicate that, similar to host humoral responses to HCMV gB, anti-gB antibodies are an integral part of humoral immunity to RhCMV infection and probably play an important protective role in limiting the extent of RhCMV infection. Thus, the rhesus macaque model of HCMV infection is relevant for testing gB-based immune therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645918     DOI: 10.1099/vir.0.19508-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  28 in total

1.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

2.  Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway.

Authors:  Timothy C Cheung; Ian R Humphreys; Karen G Potter; Paula S Norris; Heather M Shumway; Bonnie R Tran; Ginelle Patterson; Rochelle Jean-Jacques; Miri Yoon; Patricia G Spear; Kenneth M Murphy; Nell S Lurain; Chris A Benedict; Carl F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

3.  Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission.

Authors:  Kristy M Bialas; Takayuki Tanaka; Dollnovan Tran; Valerie Varner; Eduardo Cisneros De La Rosa; Flavia Chiuppesi; Felix Wussow; Lisa Kattenhorn; Sheila Macri; Erika L Kunz; Judy A Estroff; Jennifer Kirchherr; Yujuan Yue; Qihua Fan; Michael Lauck; David H O'Connor; Allison H S Hall; Alvarez Xavier; Don J Diamond; Peter A Barry; Amitinder Kaur; Sallie R Permar
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

4.  Use of specific-pathogen-free (SPF) rhesus macaques to better model oral pediatric cytomegalovirus infection.

Authors:  Myra G dela Pena; Lisa Strelow; Peter A Barry; Kristina Abel
Journal:  J Med Primatol       Date:  2012-06       Impact factor: 0.667

5.  Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  Vaccine       Date:  2020-01-31       Impact factor: 3.641

6.  Inclusion of the Viral Pentamer Complex in a Vaccine Design Greatly Improves Protection against Congenital Cytomegalovirus in the Guinea Pig Model.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

7.  Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.

Authors:  Kristina Abel; Joy Martinez; Yujuan Yue; Simon F Lacey; Zhongde Wang; Lisa Strelow; Anindya Dasgupta; Zhongqi Li; Kimberli A Schmidt; Kristie L Oxford; Basel Assaf; Jeffrey A Longmate; Don J Diamond; Peter A Barry
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

8.  Requirements for guinea pig cytomegalovirus tropism and antibody neutralization on placental amniotic sac cells.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2020-02-18       Impact factor: 3.891

9.  A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.

Authors:  Kristina Abel; Lisa Strelow; Yujuan Yue; Meghan K Eberhardt; Kimberli A Schmidt; Peter A Barry
Journal:  Vaccine       Date:  2008-08-27       Impact factor: 3.641

10.  Unique pattern of enzootic primate viruses in Gibraltar macaques.

Authors:  Gregory A Engel; Mark Pizarro; Eric Shaw; John Cortes; Agustin Fuentes; Peter Barry; Nicholas Lerche; Richard Grant; Douglas Cohn; Lisa Jones-Engel
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.